J&J Medical Connect
IMAAVY®

(nipocalimab-aahu)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY - Effect on Ocular Manifestations in Patients with Generalized Myasthenia Gravis

Last Updated: 11/19/2026

SUMMARY

  • The company cannot recommend any practices, procedures, or usage of IMAAVY that deviate from the approved labeling.
  • In the overall VIVACITY-MG3 efficacy analysis population at week 24, patients receiving IMAAVY + standard of care (SOC) showed greater improvement in ocular Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores vs placebo (PBO) + SOC1:
    • The odds ratio (OR) of achieving a ≥1-point improvement was 1.603 for the double vision MG-ADL item (95% confidence interval [CI]: 0.905-2.841) and 1.843 for the eyelid droop MG-ADL item (95% CI: 1.055-3.217).
    • The OR of achieving a ≥2-point improvement in the overall MG-ADL-ocular domain was 2.88 (95% CI: 1.526-5.436).
  • In the moderate-to-severe ocular manifestation (MSOM) population of the
    VIVACITY-MG3 trial, the least squares (LS) mean (standard error [SE]) change from baseline in MG-ADL total score was -4.71 (0.50) with IMAAVY and -3.24 (0.50) with PBO. The median (interquartile range [IQR]) change from baseline in MG-ADL ocular domain score was -2.00 (-3.0 to -0.5) with IMAAVY and -1.00 (-1.5 to 0.0) with PBO.2

CLINICAL DATA

VIVACITY-MG3

Farmakidis et al (2025)1 conducted a post-hoc analysis of VIVACITY-MG3 to evaluate if changes in MG-ADL-total score with IMAAVY + SOC vs PBO + SOC were driven by individual items, domains, or distinct muscle function groups. Claeys et al (2026)2 conducted a post-hoc analysis of VIVACITY-MG3 to evaluate the efficacy of IMAAVY vs PBO in a subgroup of patients with generalized myasthenia gravis (gMG) and MSOM.

Study Design/Methods

  • The VIVACITY-MG3 study evaluated the efficacy and safety of IMAAVY in adults with gMG in a phase 3, randomized, multicenter, double-blind, PBO-controlled study.3
  • Patients (≥18 years of age) with anti-acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), or low-density lipoprotein receptor 4 (LRP4) antibody-positive or seronegative (in all countries except France) gMG (Myasthenia Gravis Foundation of America [MGFA] class IIa-IVb) were included in the study.3
    • Eligible patients had MG-ADL scores of ≥6 at both screening and baseline.2
    • The safety analysis population included all randomized patients who received ≥1 dose (partial or complete) of any study treatment in the double-blind phase.3
    • The efficacy analysis population included all patients from the safety analysis set who had anti-AChR, anti-MuSK or anti-LRP4 antibody positive gMG.3
  • The study consisted of a ≤4-week screening phase, followed by a 24-week,
    double-blind, PBO-controlled treatment phase, a variable-duration, open-label extension phase, and a safety follow-up at 8 weeks after the last infusion.3
    • Patients who withdrew or discontinued after receiving any amount of the study intervention were required to complete a safety follow-up assessment at 8 weeks after the last dose.
  • Eligible patients were randomized (1:1) to receive either a loading dose of intravenous IMAAVY 30 mg/kg at week 0, followed by 15 mg/kg every 2 weeks (Q2W) or matching PBO through week 24 in addition to SOC therapy.3
  • The MG-ADL scale includes two items in the ocular domain (double vision and eyelid droop), each scored from 0 to 3 to assess eye-related symptoms in myasthenia gravis (0: normal; 1: occurs, but not daily; 2: daily, but not constant; 3: constant).1
  • In the Farmakidis et al post-hoc analysis, mean change from baseline in the ocular
    MG-ADL domain and change of ≥1-point on MG-ADL items were evaluated.1
  • In the Claeys et al post-hoc analysis, the MSOM population was defined as patients with a baseline score of ≥2 points on either the diplopia or ptosis items of the MG-ADL scale.2
    • The endpoints assessed change from baseline at week 24 in MG-ADL total score,
      MG-ADL ocular domain score, and MG-ADL item scores for diplopia and ptosis; the proportions of patients achieving MG-ADL minimum clinical improvement (MCI) and a ≥2-point within-patient improvement in MG-ADL ocular domain score; and the proportions of patients sustaining ≥2-point improvements in MG-ADL total and ocular domain scores over 24 weeks.
    • Change from baseline in quantitative myasthenia gravis (QMG) total and ocular domain scores, achievement of QMG MCI (≥3-point improvement), and sustained QMG MCI responses over 24 weeks were also assessed.

Results

MG-ADL Item Outcomes (Ocular Domain)

Baseline MG-ADL Item Score Distribution (Ocular Domain)1
Score
Double Vision (%)
Eyelid Droop (%)
IMAAVY + SOC (n=77)
PBO + SOC (n=76)
IMAAVY + SOC (n=77)
PBO + SOC (n=76)
0
26.3
25.0
17.1
19.7
1
22.4
35.5
21.1
27.6
2
27.6
27.6
40.8
32.9
3
23.7
11.8
21.1
19.7
Abbreviations: MG-ADL, Myasthenia Gravis-Activities of Daily Living; PBO, placebo; SOC, standard of care.
  • At week 24, patients receiving IMAAVY + SOC were more likely to achieve a ≥1-point improvement in ocular MG-ADL items compared to PBO + SOC1:
    • Double vision: OR, 1.603 (95% CI: 0.905-2.841)
    • Eyelid droop: OR, 1.843 (95% CI: 1.055-3.217)
  • At week 24, patients receiving IMAAVY + SOC showed numerically greater improvement in the ocular MG-ADL domain, with a mean change from baseline of -1.3 vs -0.6, and a significantly higher likelihood of achieving a ≥2-point improvement in this domain (OR, 2.88; 95% CI: 1.526-5.436) compared to PBO + SOC.1
Clinical Outcomes in MSOM Subgroup
  • At baseline, patients in the MSOM subgroup receiving IMAAVY (n=54) and PBO (n=51) were comparable except for MG-ADL-ocular and QMG ocular scores.2 See Table: Baseline and Demographics.

Baseline and Demographics2
IMAAVY
(n=54)

PBO
(n=51)

Age, years, mean (SD)
52.5 (15.6)
53.5 (16.8)
Female, n (%)
34 (63.0)
28 (54.9)
Race, n (%)
   Asian
16 (29.6)
17 (33.3)
   Black or African American
1 (1.9)
1 (2.0)
   White
34 (63.0)
31 (60.8)
   Other or not reported
3 (5.6)
2 (3.9)
BMI, kg/m2, mean (SD)
27.6 (5.6)
29.2 (5.8)
Duration of MG (years), mean (SD)
7.3 (8.0)
9.2 (8.9)
MG-ADL-total, mean (SD)
10.1 (2.8)
9.4 (1.9)a
MG-ADL-ocular, mean (SD)
4.1 (1.2)
3.5 (1.0)
MG-ADL diplopia, mean (SD)
2.0 (1.0)
1.5 (1.0)
MG-ADL ptosis, mean (SD)
2.2 (0.7)
1.9 (0.8)
QMG total, mean (SD)b
15.9 (5.1)
16.0 (4.9)
QMG ocular domain, mean (SD)b
4.9 (1.8)
4.3 (1.7)
MGFA classes, n (%)
   I
1 (1.9)
0
   IIa
5 (9.3)
7 (13.7)
   IIb
9 (16.7)
7 (13.7)
   IIIa
23 (42.6)
17 (33.3)
   IIIb
10 (18.5)
11 (21.6)
   Iva
2 (3.7)
7 (13.7)
   IVb
4 (7.4)
2 (3.9)
Abbreviations: BMI, body mass index; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SD, standard deviation.
an=50.
bn=52 for IMAAVY group; n=50 for PBO group.

Myasthenia Gravis Activities of Daily Living

Change from Baseline in MG-ADL Total Score and Ocular Outcomes at Week 242
Endpoint
IMAAVY
(n=41)

PBO
(n=41)

P-Value
MG-ADL total score,
LS mean (SE)

-4.71 (0.50)
-3.24 (0.50)
0.042a
MG-ADL ocular domain score, median (IQR)
-2.00 (-3.0 to -0.5)
-1.00 (-1.5 to 0.0)
0.024a
MG-ADL diplopia, median (IQR)
-1.00 (-1.0 to 0.0)
-0.00 (-0.5 to 0.0)
0.057a
MG-ADL ptosis score, median (IQR)
-1.00 (-2.0 to 0.0)
-0.50 (-1.0 to 0.0)
0.101a
Abbreviations: IQR, interquartile range; LS, least squares; MG-ADL, Myasthenia Gravis-Activities of Daily Living; PBO, placebo; SE, standard error.
aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.

  • At week 24, the proportion of patients achieving MG-ADL MCI was 64.8% in the IMAAVY group and 47.1% in the PBO group.
    • The OR (95% CI) for achieving MG-ADL MCI was 4.10 (1.42-11.86) with IMAAVY vs PBO. Over the 24-week treatment period, OR (95% CI) for achieving MG-ADL MCI was 1.79 (0.95-3.37) with IMAAVY vs PBO.
  • Sustained meaningful within-person improvement (MWPI, a ≥2-point improvement in MG-ADL total score) is presented in Table: Sustained MG-ADL Total Score ≥2-Point Improvement.

Sustained MG-ADL Total Score ≥2-Point Improvement2
Duration of Sustained Improvement
PBO
(n=51), %

IMAAVY
(n=54), %

OR (95% CI)
P-Value
≥8 weeks
60.8
68.5
1.40 (0.63-3.14)
0.422a
≥12 weeks
43.1
63.0
2.24 (1.02-4.90)
0.051a
≥16 weeks
33.3
55.6
2.50 (1.13-5.52)
0.031a
≥20 weeks
31.4
48.1
2.03 (0.92-4.51)
0.111a
Abbreviations: CI, confidence interval; MG-ADL, Myasthenia Gravis-Activities of Daily Living; OR, odds ratio; PBO, placebo.
Note: P-values are based on Fisher’s exact test.
aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.

  • At week 24, the proportion of patients achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 40.7% in the IMAAVY group and 19.6% in the PBO group.
    • At week 24, OR (95% CI) for achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 3.47 (1.34-8.97) with IMAAVY vs PBO. Over the 24-week treatment period, OR (95% CI) for achieving a ≥2-point within-person improvement in MG-ADL ocular domain score was 2.74 (1.36-5.52) with IMAAVY vs PBO.
  • Sustained MWPI (a ≥2-point improvement in MG-ADL ocular domain score) is presented in Table: Sustained MG-ADL Ocular Domain ≥2-Point Improvement.

Sustained MG-ADL Ocular Domain ≥2-Point Improvement2
Duration of Sustained Improvement
PBO
(n=51), %

IMAAVY
(n=54), %

OR (95% CI)
P-Value
≥8 weeks
23.5
38.9
2.07 (0.89-4.83)
0.098a
≥12 weeks
17.6
35.2
2.53 (1.02-6.30)
0.049a
≥16 weeks
13.7
25.9
2.20 (0.81-6.00)
0.146a
≥20 weeks
9.8
20.4
2.35 (0.76-7.33)
0.177a
Abbreviations: CI, confidence interval; MG-ADL, Myasthenia Gravis-Activities of Daily Living; OR, odds ratio; PBO, placebo.
Note: P-values are based on Fisher’s exact test.
aThese endpoints were not adjusted for multiple comparisons. Therefore, the P-values displayed are nominal, and statistical significance has not been established.

  • At week 24, a ≥1-point improvement in the MG-ADL diplopia item was achieved by 51.2% of patients in the IMAAVY group and 24.4% of patients in the PBO group (OR [95% CI]: 3.26 [1.27-8.33]).
  • At week 24, a ≥1-point improvement in the MG-ADL ptosis item was achieved by 56.1% of patients in the IMAAVY group and 43.9% of patients in the PBO group (OR [95% CI]: 1.63 [0.68-3.91]).
Quantitative Myasthenia Gravis
  • At week 24, QMG MCI was achieved by 37.0% of patients in the IMAAVY group and 23.5% of patients in the PBO group (OR [95% CI]: 3.01 [1.19-7.66]).2
    • Throughout the 24-week treatment period, OR (95% CI) for achieving QMG MCI was 3.75 (1.93-7.29).
    • A greater percentage of patients receiving IMAAVY than PBO achieved sustained QMG total score MCI responses (a ≥3-point improvement) for ≥8, ≥12, ≥16, and ≥20 consecutive weeks.
  • At week 24, the median (IQR) change from baseline in QMG ocular domain score was
    -2.00 (-3.0 to 0.0) in the IMAAVY group and -0.25 (-1.5 to 0.5) in the PBO group.
Safety (Overall VIVACITY-MG3 Cohort)
  • The proportion of patients who reported related adverse events (AEs), per investigator assessment, was 29% in both the IMAAVY (28/98) and PBO (28/98) groups.3
  • Any serious adverse events were reported in 9% (9/98) and 14% (14/98) of patients in the IMAAVY and PBO groups, respectively.3
  • The most common AEs occurring in ≥10% of patients in the IMAAVY group compared to the PBO group were coronavirus disease 2019 (COVID-19)-associated AEs (15% vs 12%), headache (14% vs 17%), muscle spasms (12% vs 3%), myasthenia gravis (12% vs 12%), and peripheral edema (12% vs 2%).3,4

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 29 September 2026.

 

References

1 Farmakidis C, Gandhi K, Ait-Tihyaty M, et al. Symptom severity assessment using MG-ADL items and domains in a 24-week, phase 3 study (Vivacity) of nipocalimab in generalized myasthenia gravis. Poster presented at: Myasthenia Gravis Foundation of America (MGFA) Scientific Session of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting; October 15-18, 2024; Savanah, Georgia.  
2 Claeys AG, Yang H, Gandhi K, et al. Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study. Expert Opinion on Biological Therapy. 26(9):997-1007.  
3 Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116.  
4 Data on File. Nipocalimab Company Core Data Sheet v005. Janssen Research & Development, LLC. EDMS-RIM-1007434; 2026.  

Would you like to clear and leave your conversation? Message history will be lost.